Introduction

Meneldor offers investors access to carefully curated co-investments in early to Phase III biotech and pharma – a space that is complex, has high-risk and potentially yields high-returns. We focus on meaningful, innovative and feasible therapies that have the potential to change standards of care, not just incrementally improve them.

We always start with the science. Only when the underlying biology, data and development path are compelling do we assess the other critical dimensions: strength of IP, clarity of medical need, market potential, competitive landscape, risk profile, execution capability, funding requirements and valuation.

In our experience, breakthrough science only turns into value when it is driven by teams with the expertise, judgment and execution power to take it through development.

Only a select group of opportunities passes this filter. When they do, Meneldor invests its own capital and invites its investors to participate on the same carefully negotiated terms.

For more information: www.meneldor.nl

This website is intended exclusively for professional and qualified investors. It is not directed at retail investors or consumers.